Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0519-0130 versus semaglutide and placebo in chronic kidney disease with overweight or obesity
2024-510846-15-00Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2025
- Modality
- Small Molecules, Peptides
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of NNC0519-0130 in chronic kidney disease (CKD), obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in urinary albumin-to-creatinine ratio. Started Apr 2025; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
chronic kidney disease (CKD)obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-510846-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510846-15-00.